Jazz Pharmaceuticals (JAZZ) SVP reports share award and open-market sales

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals SVP and Chief Accounting Officer Patricia Carr reported a mix of share awards and sales. On February 26, 2026, she received a grant of 2,223 restricted stock units under the company’s 2011 Equity Incentive Plan, with each unit convertible into one ordinary share. These units vest in equal annual installments over four years starting on March 5, 2026.

Also on February 26, 2026, she executed an open-market sale of 1,253 ordinary shares at a weighted average price of $194.1119, in multiple trades between $193.7300 and $194.4100, and shares were sold to satisfy tax obligations from vesting restricted stock units. On February 27, 2026, she sold an additional 1,117 ordinary shares at an average price of $190.9073. After these transactions, she directly held 9,235 ordinary shares.

Insider Trade Summary

Net Seller: 2,370 shares ($456,466)

Net Sell 3 txns

Insider Carr Patricia

Role SVP, Chief Accounting Officer

Sold 2,370 shs ($456K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,117	$190.9073	$213K
Grant/Award	Ordinary Shares	2,223	$0.00	--
Sale	Ordinary Shares	1,253	$194.1119	$243K

Holdings After Transaction: Ordinary Shares — 9,235 shares (Direct)

Footnotes (1)

These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.7300 to $194.4100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Form 4 Insider Transactions: What Each Field Means →

03/02/2026 - 05:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Patricia

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	02/26/2026		A⁽¹⁾		2,223	A	$0.0	11,605	D
Ordinary Shares	02/26/2026		S⁽²⁾		1,253	D	$194.1119⁽³⁾	10,352	D
Ordinary Shares	02/27/2026		S		1,117	D	$190.9073	9,235	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.

2. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

3. Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $193.7300 to $194.4100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

	By: /s/Paz Dizon, as attorney in fact For: Patricia Carr	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Patricia Carr report for Jazz Pharmaceuticals (JAZZ)?

Patricia Carr reported one equity award and two share sales. She received 2,223 restricted stock units, then sold a total of 2,370 ordinary shares in open-market transactions while retaining 9,235 shares held directly afterward.

How many Jazz Pharmaceuticals (JAZZ) shares did Patricia Carr sell and at what prices?

She sold 1,253 ordinary shares at a weighted average price of $194.1119, in trades between $193.73 and $194.41, and 1,117 shares at an average price of $190.9073, for total reported sales of 2,370 shares.

What equity award did Patricia Carr receive from Jazz Pharmaceuticals (JAZZ)?

She received a grant of 2,223 restricted stock units under Jazz Pharmaceuticals’ 2011 Equity Incentive Plan. Each unit represents a contingent right to receive one ordinary share when the units vest according to the stated schedule.

What is the vesting schedule for Patricia Carr’s new Jazz Pharmaceuticals (JAZZ) restricted stock units?

The 2,223 restricted stock units vest in four equal annual installments starting from March 5, 2026. One-quarter vests on the first anniversary, with the remaining three-quarters vesting in equal annual installments over the following three years.

Why were some Jazz Pharmaceuticals (JAZZ) shares sold by Patricia Carr?

A portion of the reported share sales was used to satisfy tax obligations from the vesting of previously granted restricted stock units. Such tax-related sales are common when equity awards convert into shares and trigger taxable income for the recipient.

How many Jazz Pharmaceuticals (JAZZ) shares does Patricia Carr hold after these transactions?

Following the award and subsequent sales, Patricia Carr directly holds 9,235 ordinary shares of Jazz Pharmaceuticals. This figure reflects her reported direct ownership after all listed transactions were completed on February 26 and 27, 2026.